[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
Hyperphosphatemia is a serious complication which has been linked with an increased risk of cardiovascular mortality in patients with chronic kidney disease. Lanthanum carbonate is a novel non-calcium, non-aluminum phosphate-binding agent, and has approved for clinical use in patients on hemodialysis in Japan on March in 2009. Compared to calcium carbonate and sevelamer hydrochloride, lanthanum carbonate is a powerful phosphate binder. There is no evidence of bone toxicity and neurotoxicity of lanthanum carbonate previously reported for aluminium hydroxide. However, further studies are needed to address the longer term toxic effect on bone and other organs.
Negi
Shigeo
S
Division of Nephrology&Blood Purification Medicine, Wakayama Medical University.
Shigematsu
Takashi
T
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002908:Chronic Disease; D015195:Drug Design; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology*; D007674:Kidney Diseases / Q000150:complications*; D007811:Lanthanum / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects; D012306:Risk
C119467:lanthanum carbonate; D007811:Lanthanum